Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
Tel: 317-276-2000
Website: http://www.lilly.com/
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2188 articles with Eli Lilly and Company
-
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
-
If the company does sell some older assets, it could use the funds to support development of high-growth assets in immuno-oncology.
-
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache
11/14/2018
Lilly also plans to submit a supplemental Biologics License Application (sBLA) to the FDA for Emgality for the preventive treatment of episodic cluster headache by the end of the year, reflecting its commitment to disabling headache disorders
-
The Food and Drug Administration is taking care of a few approvals and committee meetings ahead of the Thanksgiving holiday week. They include drugs for COPD, a pain drug, and a sublingual film formulation of a well-known drug for erectile dysfunction. Here’s a look.
-
Lilly to Participate in Credit Suisse 27th Annual Healthcare Conference
11/8/2018
Eli Lilly and Company will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13, 2018. Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will participate in a fireside chat at 3:40 p.m., Eastern Time.
-
Indianapolis-based Eli Lilly pulled another BACE therapy from its pipeline, the company announced in a third-quarter conference call.
-
Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance
11/6/2018
Third-quarter 2018 revenue increased 7 percent, driven primarily by increased demand for new medicines, while operating expenses increased 1 percent.
-
Lilly is paying NextCure $25 million upfront. NextCure will be eligible for various development and commercial milestone payments, as well as royalties on any commercial products. In addition, Lilly invested $15 million in NextCure equity.
-
Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes
11/5/2018
Only 31 percent of REWIND trial participants had established CV disease
-
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
11/5/2018
Jardiance (empagliflozin) was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors
-
Indianapolis-based Eli Lilly announced that its diabetes drug Trulicity (dulaglutide) reduced major adverse cardiovascular events (MACE) in its REWIND clinical trial.
-
Top 12 Life Science Companies Hiring Now
11/2/2018
Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now! -
In October 1982, the Food and Drug Administration (FDA) approved Eli Lilly and Company’s Humulin, the first human insulin for diabetes treatment created using recombinant DNA technology.
-
Biopharma companies set to release financial reports next week have reported positive news in recent months.
-
Lilly and Dicerna Announce RNAi Licensing and Research Collaboration
10/29/2018
Companies will collaborate on RNAi research for cardio-metabolic, neurodegeneration and pain targets
-
For the second time in less than one week, Dicerna Pharmaceutical has forged a licensing agreement for its GalXC RNAi technology platform. This time Dicerna and Eli Lilly have struck an agreement to use the platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.
-
BioSpace Movers and Shakers Oct. 29
10/29/2018
Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more. -
New Hope for Drug Discovery in Schizophrenia, Other Diseases With Improved Screening Models
10/25/2018
Proof-of-concept study indicates utility of patient-derived cells for evaluating drug response
-
Eli Lilly Updates Spondyloarthritis Trial Data and Long-Term Rheumatoid Arthritis Studies
10/24/2018
Eli Lilly and Company presented positive data from two Phase III clinical trials at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago yesterday. -
Eli Lilly and Company and Pfizer presented complete results from a Phase III clinical trial of tanezumab in patients with osteoarthritis (OA) at the 2018 American College of Rheumatology/Association of Rheumatology for Health Professionals (ACR/ARHP) Annual Meeting in Chicago.